1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends

Circulating Tumor Cell (CTC) Diagnostics: Technologies and Global Markets

  • January 2014
  • 237 pages
  • BCC Research
Report ID: 2009162

Summary

Table of Contents

STUDY GOALS AND OBJECTIVES

This report, PHM153A – Circulating Tumor Cell (CTC) Diagnostic: Technologies and Global Markets, gives market insight on monitoring tests used for cancer prognoses. The market is analyzed by cancer type: prostate, breast and colorectal. This report analyzes the circulating tumor cells market, including technologies as well as commercial perspective and describes the overall market size, industry growth rate and market trends. It gives a summary of the recent developments in the CTC market and includes detailed profiles of key players.
The report’s focus is on circulating tumor cell testing and monitoring methods. The report also includes an overview on cancer, diagnostic strategies and treatment technologies. Important trends in the field of cancer research and development have been reviewed in this report, and sales forecasts by treatment and screening categories are provided from 2013 through 2018. Issues and trends addressed in this report are based on information from industry sources, regulatory and healthcare policies, demographics and other factors that directly affect the circulating tumor cell market.

REASONS FOR DOING THIS STUDY

This study was conducted to provide detailed information regarding new developments, testing and treatment options for cancer. There is an increasing need for new and innovative technologies. This industry is experiencing growth; the use of new diagnostic technologies for cancer has increased in the past few years.
This BCC Research study will increase the awareness of current and emerging technologies and diagnostics for cancer, especially prostate, breast and colorectal cancer.

INTENDED AUDIENCE

This report is an exhaustive study on the global cancer market with important incidence statistics and analysis of diagnostic technologies, latest trends, market structure, market size, key drug segments and trends in technology. This study contributes to the areas of market growth in circulating tumor cells and diagnostic strategies for metastatic cancer. This study will be of interest largely to the pharmaceutical and biotechnology industries, as well as to clinics, hospitals and research institutes. Also, this report may prove crucial for investment firms with involvement in this sector. The report shows tests currently being used for cancer diagnosis and prognosis, new developments, spending trends and revenue prospects for these technologies. The report provides market data for 2012 to 2018 and also covers commercial prospects for cancer diagnostic assays and tests currently in use and that are forecast for future use.

SCOPE OF THE STUDY

The scope of this study is clinical testing, prognostic and monitoring markets for CTCs in cancer. The report also includes the clinical segment, currently approved CTC tests and their markets, the regulatory environment, current technologies, new technologies, cancer incidence, market projections and market share along with the latest trends and new developments in this area. This report does not include the segment’s research market including reagents, or any accessories used for CTC isolation or studies. The research segment of the market includes numerous competitors with different capabilities, developing and commercializing products such as CTC isolation devices and protocols, CTC characterization reagents, assay and instrumentation, and various identification technologies based on cell imaging. These market players include specialized or research-based companies that contribute considerably to the technological advancements in the field of CTC technologies. The data collected for the report is focused on breast, prostate and colorectal cancers for which clinical data and tests are available currently on the market. CTCs in other cancers are being researched and some are in clinical trials; these are not included within the scope of this report.

METHODOLOGY

Both primary and secondary research methodologies were used in preparing this report. Secondary sources include books, newspapers, trade journals, white papers, industry portals, government agencies, trade associations, monitoring industry news and developments, and through access to paid and free databases. The base year of the report is 2012, with forecast data provided through 2018. Historical, base year and forecast data are provided for each market segment of this report.
The report provides a comprehensive review of cancer incidence and development of the disease, drugs currently being used and diagnostic technologies. The report also reviews technological developments, product innovations/introductions and recent strategic industry activity of major players across various product categories. Growth rates, global incidence and projections are determined through a compilation of data including past trends, future trends, demographics, incidence, mortality, products in R&D, current product growth, etc. Forecasts and projections were based on estimates such as the current trends, potential users, mergers and acquisitions, and market trends.
A comprehensive and exhaustive search of the literature on prostate cancer assay development and currently marketed products, global incidence and latest drug developments was conducted. These secondary sources include scientific–related journals and articles, textbooks, press releases, marketing literature, other product/promotional literature, annual reports, security analyst reports and other publications. A patent search and analysis was also conducted. Some informal interviews were conducted with experts and personnel in this area at biotech and pharmaceutical companies. Other resources include academics, technology and consulting companies.

INFORMATION SOURCES

Many companies within the industry were surveyed to obtain data for this study. Included were manufacturers and end users of products that include pharmaceutical and biotechnical industries, research institutes, etc. Data were gathered from various industry sources. BCC Research spoke with officials within the industry, consulted newsletters, company literature, product literature and a host of technical articles, journals, indexes and abstracts. Exhaustive investigations of databases by key terminology were completed. In addition, data were compiled from current financial, trade and government sources.

ABOUT THE AUTHOR

Usha Nagavarapu, PhD, is an experienced pharmaceutical professional with scientific and business development experience. She has managed preclinical discovery programs from target identification including investigational new drug (IND)-enabling studies, and assisted out-licensing and portfolio development activities. Her strong focus areas include oncology, dermatology and cardiovascular diseases. Usha has extensive experience working with early start-ups to fulfill operational obligations while minimizing overall operational cost and burden.

REPORT HIGHLIGHTS

The global market for circulating tumor cell (CTC) technology reached nearly $2.8 billion in 2012 and $3.7 billion in 2013. This market is estimated to reach nearly $8.9 billion by 2018, demonstrating a compound annual growth rate (CAGR) of 18.9% for the five-year period, 2013 to 2018.

This report provides:
• An overview of the global market for cancer diagnostics based on circulating tumor cells, which are used to increase understanding of tumor cell biology and metastatic cancer as a disease.
• Analyses of global market trends, with data from 2012 and 2013, and projections of compound annual growth rates for the period of 2013 to 2018.
• Discussion of the advantages and disadvantages of CTC enrichment techniques.
• Estimations of cancer incidence, cancer deaths, new cases by type in the United States, and breast cancer statistics and facts.
• Examination of growth opportunities and drivers in the CTC market and recent breakthroughs in research, along with a patent analysis.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Veronica helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Non-small cell lung cancer (NSCLC) disease forecast and market analysis to 2035

  • $ 22000
  • Industry report
  • March 2017
  • by Datamonitor Healthcare

Disease Overview Lung cancer is a disease in which the cells in lung tissue grow uncontrollably. More than 80% of lung cancers are non-small cell lung cancers (NSCLC), with the exact proportion depending ...

Renal cell cancer (RCC) disease forecast and market analysis to 2035

  • $ 22000
  • Industry report
  • March 2017
  • by Datamonitor Healthcare

Disease Overview Renal cell cancer (RCC) is a tumor that originates in the renal cortex, the outer part of the kidney between the renal capsule and the renal medulla. Around 85% of all malignant kidney ...

Frontier Pharma: First-in-Class Innovation in Hematological Cancers - Cytokine Signaling and Kinase Targeted Immunotherapies Dominate a Large and Highly Versatile Pipeline

  • $ 6995
  • Industry report
  • May 2017
  • by GBI Research

Frontier Pharma: First-in-Class Innovation in Hematological Cancers - Cytokine Signaling and Kinase Targeted Immunotherapies Dominate a Large and Highly Versatile Pipeline Summary Hematological cance ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.